HLA-G and its relation to proliferation index in detection and monitoring breast cancer patients

Tissue Antigens

Volumn 75, Issue 1, 2010, Pages 40-47

  Sayed, D ^a   Badr, G ^b   Maximous, D ^c   Mikhail, N N H ^c   Abu Tarboush, F ^b   Alhazza, I M ^b  

^a Assiut University Faculty of Medicine   (Egypt)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c ASSIUT UNIVERSITY   (Egypt)

Author keywords

Breast cancer; Flow cytometry; Human leukocyte antigen G; Proliferation index

Indexed keywords

DNA; FLUOROURACIL; HLA G ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD DONOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CELL CYCLE S PHASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; MASTECTOMY; MULTIPLE CYCLE TREATMENT; PARAMETER; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROLIFERATION INDEX; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CELL MEMBRANE; CELL PROLIFERATION; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; PLOIDIES; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 72649097516     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2009.01393.x     Document Type: Article

References (49)

1. Mc Pherson K, Steel CM, Dixon JM. ABC of the breast diseases, breast cancer epidemiology, risk factors and genetics. Br Med J 2000 : 321 : 624 628.
2. Shih I-M. Application of human leukocyte antigen-G expression in the diagnosis of human cancer. Hum Immuno 2007 : 68 : 272 276.
3. Favier B, LeMaoult J, Rouas-Freiss N, Moreau P, Menier C, Carosella ED. Research on HLA-G: an update. Tissue Antigens 2007 : 69 : 207 211.
4. Carosella ED, Moreau P, Le Maoult J, Le Discorde M, Dausset J, Rouas-Freiss N. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv Immunol 2003 : 81 : 199 252.
5. Geraghty DE, Koller BH, Orr HT. A human major histo-compatibility complex class I gene that encode a protein with a shortened cytoplasmic segment. Proc Natl Acad Sci USA 1987 : 84 : 9145 9149.
6. Ishitani A, Geraghty DE. Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc Natl Acad Sci USA 1992 : 89 : 3947 3951.
7. Menier C, Ritreau B, Dausset J, Carosella ED, Rouas-Freiss N. HLA-G truncated isoforms can substitute for HLA-G1 in fetal survival. Hum Immunol 2000 : 61 : 1118 1125.
8. Moreau P, Rousseau P, Rouas-Freiss N, Le Discorde M, Dausset J, Carosella ED. HLA-G protein processing and transport to the cell surface. Cell Mol Life Sci 2002 : 59 : 1460 1466.
9. Rouas-Freiss N, Goncalves RM, Menier C, Dausset J, Carosella ED. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci USA 1997 : 94 : 11520 11525.
10. Rebmann V, Pfeiffer K, Passler M et al. Detection of soluble HLA-G molecules in plasma and amniotic fluid. Tissue Antigens 1999 : 53 : 14 22.
11. Rebmann V, van der Van K, Passler M, Pfeiffer K, Krebs D, Grosse-Wilde H. Association of soluble HLA-G plasma levels with HLA-G alleles. Tissue Antigens 2001 : 57 : 15 21.
12. Singer G, Rebmann V, Chen YC et al. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res 2003 : 9 : 4460 4464.
13. Bukur J, Rebmann V, Grosse-Wild H et al. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res 2003 : 63 : 4107 4111.
14. Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res 2005 : 65 : 10139 10144.
15. Hansel DE, Rahman A, Wilentz RE et al. HLA-G up-regulation in pre-malignant and malignant lesions of the gastrointestinal tract. Int J Gastrointest Cancer 2005 : 35 : 15 24.
16. Kleinberg L, Florenes VA, Skrede M et al. Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch 2006 : 449 : 31 9.
17. Rebmann V, Regel J, Stolke D, Grosse-Wilde H. Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol 2003 : 13 : 371 377.
18. Davidson B, Elstrand MB, McMaster MT et al. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol Oncol 2005 : 96 : 42 7.
19. Nuckel H, Rebmann V, Durig J, Duhrsen U, Grosse Wilde H. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 2005 : 105 : 1694 1698.
20. Ishigami S, Natsumoto M, Okumura H, Douchi T, Hokita S, Aikou T. HLA-G expression in gastric cancer. Anticancer Res 2006 : 26 : 2467 2472.
21. Nowell PC. The clonal evolution of tumor cell populations. Acquired genetic liability permits stepwise selection of variant sub-lines and underlies tumor progression. Science 1976 : 194 : 23 8.
22. Polakova K, Bandzuchova E, Tirpakova J, Kuba D, Russ G. Modulation of HLA-G expression. Neoplasm 2007 : 54 : 455 462.
23. Sobin LH. Wittekind C, ed. International Union Against Cancer, TNM Classification of Malignant Tumors, Breast tumors (ICD-O C50), 5th edn. New York : Wiley-Liss, 1997, 123 130.
24. van Dam PA, Watson JV, Lowe DG, Cox H, Curling M, Sheph JH. Tissue preparation for simultaneous flow cytometric quantitation of tumor associated antigens and DNA in solid tumors. J Clin Pathol 1990 : 43 : 833 839.
25. Riley RS, Mahin EJ, Ross W, eds. Clinical Applications of Flow Cytometry. New York : Igaku Shoin Medical, 1993.
26. Rouas-Freiss N, Moreau P, Menier C, Carosella ED. HLA-G in cancer: a way to turn off the immune system. Semin Cancer Biol 2003 : 13 : 325 336.
27. Lefebvre S, Antoine M, Uzan S et al. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol 2002 : 196 : 266 274.
28. Palmisano GL, Pistillo MP, Fardin P et al. Analysis of HLA-G expression in breast cancer tissues. Hum Immunol 2002 : 63 : 969 976.
29. Real LM, Cabrera T, Canton J, Oliva R, Ruiz-Cabello F, Garrido F. Looking for HLA-G expression in human tumors. J Reprod Immunol 1999 : 43 : 263 273.
30. Schmidt CM, Ehlenfeldt RG, Athanasiou MC et al. Extraembryonic expression of the human MHC class I gene HLA-G in transgenic mice. Evidence for a positive regulatory region located 1 kilobase 5′ to the start site of transcription. J Immunol 1993 : 151 : 2633 2645.
31. Onno M, Guillaudeux T, Amiot L et al. The HLA-G gene is expressed at a low mRNA level in different human cells and tissues. Hum Immunol 1994 : 41 : 79 86.
32. Yie SM, Xiao R, Librach CL. Progesterone regulates HLA-G gene expression through a novel progesterone response element. Hum Reprod 2006 : 21 : 2538 2544.
33. LeMaoult J, Le Discorde M, Rouas-Freiss N et al. Biology and functions of human leukocyte antigen-G in health and sickness. Tissue Antigens 2003 : 62 : 273 284.
34. Barrier BF, Kendall BS, Sharpe-Timms K, Kost ER. Characterization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma. Gynecol Oncol 2006 : 103 : 25 30.
35. Ye SR, Yang H, Li K, Dong DD, Lin XM, Yie SM. Human leukocyte antigen G (HLA-G) expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol 2007 : 20 : 375 383.
36. Sebti Y, Le Friec G, Pangault C et al. Soluble HLA-G molecules are increased in lymphoproliferative disorders. Hum Immunol 2003 : 64 : 1093 1101.
37. Creput C, Durrbach A, Charpentier B, Carosella ED, Rouas-Freiss N. HLA-G: immunoregulatory molecule involved in allograft acceptance. Nephrologie 2003 : 24 : 451 456.
38. Gros F, Sebti Y, de Guibert S et al. Soluble HLA-G molecules are increased during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. Neoplasm 2006 : 8 : 223 230.
39. Rudstein-Svetlicky N, Loewenthal R, Horejsi V, Gazit E. HLA-G levels in serum and plasma. Tissue Antigens 2006 : 67 : 111 116.
40. Yie SM, Li LH, Li TM, Librach CL. HLA-G protein concentrations in maternal serum and placental tissue are decreased in pre-eclampsia. Am J Obstet Gynecol 2004 : 191 : 525 529.
41. Rosado S, Perez-Chacon G, Mellor-Pita S et al. Expression of human leukocyte antigen-G in systemic lupus erythematosus. Hum Immunol 2008 : 69 : 9 15.
42. Wastowski IJ, Sampaio-Barros PD, Amstalden EM et al. HLA-G expression in the skin of patients with systemic sclerosis. J Rheumatol 2009 : 36 : 1230 1234.
43. Amadori D, Silvestrini R. Prognostic and predictive value of thymidine labeling index in breast cancer. Breast Cancer Res Treat 1998 : 51 : 267 281.
44. Rudolph P, Alm P, Heidebrech HJ et al. Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer. J Nat Cancer Inst (Bethesda) 1999 : 91 : 271 278.
45. Romain S, Christensen IJ, Chinot O et al. Prognostic value of cytosolic thymidine kinase activity as a marker of proliferation in breast cancer. Int J Cancer 1995 : 61 : 7 12.
46. Chassevent A, Jourdan ML, Ferrero-Pous M et al. S-phase fraction and DNA ploidy in 633 T1T2 breast cancers: a standardized flow cytometric study. Clin Cancer Res 2001 : 7 : 909 917.
47. Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute T, Merkel D. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Cytometry 1993 : 14 : 482 485. (Pubitemid 23191956)
48. Shankey TV, Rabinovitch PS, Bagwell B et al. Guidelines for implementation of clinical DNA. Cytometry 1993 : 14 : 472 477.
49. Sheu JJC, Shih IM. Clinical and biological significance of HLA-G expression in ovarian cancer. Semin Cancer Biol 2007 : 17 : 436 443.